Boston Partners
BIOL

Boston Partners’s Biolase, Inc. BIOL Stock Holding History

Boston Partners’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-109
Closed -$1.23M – 770
2015
Q3 		$1.23M Sell
109
-5
-4% -$92.9K ﹤0.01% 648
2015
Q2 		$2.49M Buy
+114
New +$2.78M ﹤0.01% 599

Other funds holding BIOL

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PCMI
Princeton Capital Management Inc Princeton, New Jersey $198M AUM 28.98% 1-Year Est. Return
TA
Teton Advisors Rye, New York $142M AUM 42.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Boston Partners's BIOL Position: Q4 2015 in Review

Boston Partners sold out of Biolase, Inc. (BIOL) in Q4 2015, closing a stake of 109 shares — an estimated $1.23M sold.

Boston Partners first reported a position in BIOL in Q2 2015 and held it in 2 quarters. The position peaked at $2.49M in Q2 2015. 30 funds tracked by Wall St. Rank hold BIOL as of Q4 2015.

  • Boston Partners reported no remaining Biolase, Inc. position as of Q4 2015 after selling out during the quarter.
  • Boston Partners sold 109 Biolase, Inc. shares in Q4 2015, an estimated $1.23M.
  • Boston Partners first reported a position in Biolase, Inc. in Q2 2015 and held it in 2 quarters.
  • Boston Partners's Biolase, Inc. position peaked at $2.49M in Q2 2015.
  • 30 funds tracked by Wall St. Rank held Biolase, Inc. as of Q4 2015.

Based on Boston Partners's 13F filing for Q4 2015, filed 8 Feb 2016.